AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial

Ab­b­Vie’s Skyrizi-based com­bi­na­tion ther­a­py for in­flam­ma­to­ry bow­el dis­ease worked bet­ter than Skyrizi alone in a mid-stage tri­al in Crohn’s dis­ease, the com­pa­ny said Mon­day.

The …